Asan Medical Center

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Asan Medical Center

  Seoul, Seoul 05505

  736 trials

• Asan Medical Center - PPDS

  Seoul, 05505

  18 trials

• Asan Medical Center - Oncology

  Seoul, 5505

  15 trials

• Asan Medical Center

  SongpaGu, Seoul Teugbyeolsi 05505

  13 trials

• Asan Medical Center (AMC)

  Seoul, 05505

  9 trials

• Asan Medical Center, University of Ulsan College of Medicine

  Seoul, 05505

  9 trials

• Asan Medical Centre

  Seoul, 05505

  7 trials

• Seoul ASAN Medical Center

  Seoul, 05505

  6 trials

• Asan Medical Center

  Songpa-gu, 5505

  5 trials

• Asan Medical Center_Endocrinology

  Seoul, 05505

  3 trials

  • NCT07931599A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

    Contact: Novo Nordisk

  • NCT07668388A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Contact: Novo Nordisk

  • NCT07533175AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

• Asan Medical Center (Site 3004)

  Seoul, 05505

  3 trials

  • NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

  • NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  • NCT05952856A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

• Asan Medical Center-Department of Oncology (Site 3901)

  Seoul, 05505

  2 trials

  • NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

  • NCT05319730A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

    Contact: Study Coordinator

• Asan Medical Center (Site 1303)

  Seoul, 05505

  2 trials

  • NCT06925750A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  • NCT06664801A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

• Asan Medical Center (Site 1803)

  Seoul, 05505

  2 trials

  • NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Contact: Study Coordinator

  • NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

• Asan Medical Center (Site 2402)

  Seoul, 05505

  2 trials

  • NCT04895358Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

  • NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

• Asan Medical Center (Site 2901)

  Seoul, 05505

  2 trials

  • NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

    Contact: Study Coordinator

  • NCT07405151A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

    Contact: Study Coordinator

• Asan Medical Center, University of Ulsan

  Seoul

  2 trials

  • NCT06616766A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

    Contact: Dae Ho Lee

  • NCT06247280Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation

• Asan Medical Center, Univ. of Ulsan

  Seoul, 05505

  2 trials

  • NCT06787612Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

    Contact: Clinical Trials Administrator

  • NCT03564340Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

    Contact: Clinical Trials Administrator

• University of Ulsan College of Medicine - Asan Medical Center (AMC)

  Seoul, 05505

  2 trials

  • NCT05359861Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  • NCT04646005Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

• 4100018 - Asan Medical Center

  Seoul, 05505

  1 trial

  • NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

• Asan Medical Center

  Songpa-dong, Seoul 05505

  1 trial

  • NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

    Contact: Nikki Nepomuceno

• Asan Medical Center (AMC) - Site #111

  Seoul, Seoul Teugbyeoisi 18450

  1 trial

  • NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

• Asan Medical Center, Asian Cacer Center

  Seoul

  1 trial

  • NCT04459715A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

• Asan Medical Center_Cardiology

  Seoul, 05505

  1 trial

  • NCT07567001A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    Contact: Novo Nordisk

• Asan Medical Center / Clinical Trial Center

  Seoul, 138-736

  1 trial

  • NCT04225715A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

• Asan Medical Center, Department of Oncology

  Seoul, 05505

  1 trial

  • NCT04862780(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

• Asan Medical Center-Department of Oncology (Site 0405)

  Seoul, 05505

  1 trial

  • NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

• Asan Medical Center-Department of Oncology (Site 1103)

  Seoul, 05505

  1 trial

  • NCT04924101Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

• Asan Medical Center-Department of Oncology (Site 1105)

  Seoul, 05505

  1 trial

  • NCT04895722Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

• Asan Medical Center-Department of Oncology (Site 1300)

  Seoul, 05505

  1 trial

  • NCT04704219Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

• Asan Medical Center-Department of Oncology (Site 1703)

  Seoul, 05505

  1 trial

  • NCT05508867A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

• Asan Medical Center-Department of Oncology (Site 1901)

  Seoul, 05505

  1 trial

  • NCT05342636A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

• Asan Medical Center-Department of Oncology (Site 2352)

  Seoul, 05505

  1 trial

  • NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    Contact: Toll Free Number

• Asan Medical Center-Department of Oncology (Site 3103)

  Seoul, 05505

  1 trial

  • NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    Contact: Study Coordinator

• Asan Medical Center-Department of Oncology (Site 3501)

  Seoul, 05505

  1 trial

  • NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

• Asan Medical Center-Department of Oncology (Site 4901)

  Seoul, 05505

  1 trial

  • NCT06483334A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

• Asan Medical Center-Department of Oncology (Site 5901)

  Seoul, 05505

  1 trial

  • NCT06469944Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

    Contact: Study Coordinator

• Asan Medical Center-Department of Oncology (Site 7901)

  Seoul, 05505

  1 trial

  • NCT06445972Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

    Contact: Study Coordinator

• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 2303)

  Seoul, 05505

  1 trial

  • NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 2304)

  Seoul, 05505

  1 trial

  • NCT05116189Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 3401)

  Seoul, 05505

  1 trial

  • NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

• Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology (Site 3501)

  Seoul, 05505

  1 trial

  • NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

• Asan Medical Center, Division of Oncology, Department of Internal Medicine

  Seoul, 05505

  1 trial

  • NCT01740427A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

• Asan Medical Center /ID# 125601

  Seoul, 05505

  1 trial

  • NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

• Asan Medical Center /ID# 142974

  Seoul, 05505

  1 trial

  • NCT02629159A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

• Asan Medical Center /ID# 158696

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

• Asan Medical Center /ID# 159155

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• Asan Medical Center /ID# 204236

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• Asan Medical Center /ID# 214294

  Seoul, 05505

  1 trial

  • NCT04169373A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

• Asan Medical Center /ID# 219054

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

• Asan Medical Center /ID# 221227

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

• Asan Medical Center /ID# 222280

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04189614An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

• Asan Medical Center /ID# 225758

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

• Asan Medical Center /ID# 228444

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05409066Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

• Asan Medical Center /ID# 230282

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04807972Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

• Asan Medical Center /ID# 231886

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

• Asan Medical Center /ID# 234273

  Seoul, 05505

  1 trial

  • NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

• Asan Medical Center /ID# 238912

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04433442Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

• Asan Medical Center /ID# 240286

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT03891446Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

• Asan Medical Center /ID# 242400

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05283720A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

• Asan Medical Center /ID# 242409

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06508658A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

• Asan Medical Center /ID# 245215

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05029882Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

• Asan Medical Center /ID# 251312

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04541810A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

• Asan Medical Center /ID# 252289

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

• Asan Medical Center /ID# 253044

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05822752Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

• Asan Medical Center /ID# 253955

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06068868Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

• Asan Medical Center /ID# 254022

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05843643Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

• Asan Medical Center /ID# 257845

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

• Asan Medical Center /ID# 259255

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

• Asan Medical Center /ID# 260010

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06191744Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

• Asan Medical Center /ID# 263220

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05512390A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

• Asan Medical Center /ID# 264228

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06468228A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

• Asan Medical Center /ID# 266341

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05618028Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

• Asan Medical Center /ID# 266799

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT03821935Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

• Asan Medical Center /ID# 268717

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06614192A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

• Asan Medical Center /ID# 269480

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

• Asan Medical Center /ID# 270898

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

• Asan Medical Center /ID# 272130

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

• Asan Medical Center /ID# 274454

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07023289A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

• Asan Medical Center /ID# 275600

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

• Asan Medical Center /ID# 276955

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

• Asan Medical Center /ID# 277371

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

• Asan Medical Center /ID# 277603

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

• Asan Medical Center /ID# 279395

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

• Asan Medical Center /ID# 282732

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07525206A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

• Asan Medical Center: Medical Oncology Department

  Seoul

  1 trial

  • NCT02811861Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

• Asan Medical Center - Oncology Department

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT04423718Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

• Asan Medical Center - Pulmonology

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT07209761A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

    Contact: Otsuka Cell Center

• ASAN Medical Center (Seoul)

  Seoul, 05505

  1 trial

  • NCT02052778A Study of TAS-120 in Patients With Advanced Solid Tumors

• Asan Medical Center (Site 0006)

  Seoul, Seoul 05505

  1 trial

  • NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

• Asan Medical Center (Site 0031)

  Seoul, 05505

  1 trial

  • NCT06686394Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    Contact: Study Coordinator

• Asan Medical Center (Site 0064)

  Seoul, 05505

  1 trial

  • NCT05609968Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

• Asan Medical Center (Site 0072)

  Seoul, 05505

  1 trial

  • NCT03062358Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

• Asan Medical Center (Site 0076)

  Seoul, 05505

  1 trial

  • NCT03829332Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

• Asan Medical Center (Site 0082)

  Seoul, 05505

  1 trial

  • NCT03221426Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

• Asan Medical Center (Site 0163)

  Seoul, 05505

  1 trial

  • NCT06428409A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    Contact: Study Coordinator

• Asan Medical Center (Site 0200)

  Seoul, 05505

  1 trial

  • NCT04241185Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

• Asan Medical Center (Site 0289)

  Seoul, 05505

  1 trial

  • NCT04740307Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

• Asan Medical Center (Site 0300)

  Seoul, 05505

  1 trial

  • NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

• Asan Medical Center (Site 0310)

  Seoul, 05505

  1 trial

  • NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

• Asan Medical Center (Site 0460)

  Seoul, Seoul-teukbyeolsi [Seoul] 05505

  1 trial

  • NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

• Asan Medical Center (Site 0503)

  Seoul, 05505

  1 trial

  • NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    Contact: Study Coordinator

• Asan Medical Center (Site 0603)

  Seoul, 05505

  1 trial

  • NCT06079879A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

• Asan Medical Center (Site 0701)

  Seoul, 05505

  1 trial

  • NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

• Asan Medical Center (Site 0830)

  Seoul, 05505

  1 trial

  • NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

• Asan Medical Center (Site 1062)

  Seoul, Seoul 05505

  1 trial

  • NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

• Asan Medical Center (Site 1102)

  Seoul, 05505

  1 trial

  • NCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

• Asan Medical Center (Site 1200)

  Seoul, 05505

  1 trial

  • NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

• Asan Medical Center (Site 1313)

  Seoul, 05505

  1 trial

  • NCT05007106MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

• Asan Medical Center (Site 1355)

  Seoul, 05505

  1 trial

  • NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

• Asan Medical Center (Site 1404)

  Seoul, 05505

  1 trial

  • NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

    Contact: Study Coordinator

• Asan Medical Center (Site 1601)

  Seoul, 05505

  1 trial

  • NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

• Asan Medical Center (Site 1602)

  Seoul, 05505

  1 trial

  • NCT06307431A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

• Asan Medical Center (Site 1800)

  Seoul, 05505

  1 trial

  • NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

• Asan Medical Center (Site 1901)

  Seoul, 05505

  1 trial

  • NCT05562830A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

• Asan Medical Center (Site 2003)

  Seoul, 05505

  1 trial

  • NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

    Contact: Study Coordinator

• Asan Medical Center (Site 2102)

  Seoul, 05505

  1 trial

  • NCT03036488Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

• Asan Medical Center (Site 2105)

  Seoul, 05505

  1 trial

  • NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    Contact: Study Coordinator

• Asan Medical Center (Site 2305)

  Seoul, 05505

  1 trial

  • NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Contact: Study Coordinator

• Asan Medical Center (Site 2500)

  Seoul, 05505

  1 trial

  • NCT07554339A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    Contact: Study Coordinator

• Asan Medical Center (Site 2501)

  Seoul, 05505

  1 trial

  • NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

    Contact: Study Coordinator

• Asan Medical Center (Site 2702)

  Seoul, 05505

  1 trial

  • NCT03615326Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

• Asan Medical Center (Site 2705)

  Seoul, 05505

  1 trial

  • NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    Contact: Study Coordinator

• Asan Medical Center (Site 2802)

  Seoul, 05505

  1 trial

  • NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

• Asan Medical Center (Site 2904)

  Seoul, 05505

  1 trial

  • NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    Contact: Study Coordinator

• Asan Medical Center (Site 3007)

  Seoul, 05505

  1 trial

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Asan Medical Center (Site 3103)

  Seoul, 05505

  1 trial

  • NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Contact: Study Coordinator

• Asan Medical Center (Site 3600)

  Seoul, 05505

  1 trial

  • NCT07431827MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

    Contact: Study Coordinator

• Asan Medical Center (Site 3609)

  Seoul, 05505

  1 trial

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• Asan Medical Center (Site 3801)

  Seoul, 05505

  1 trial

  • NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

• Asan Medical Center (Site 3803)

  Seoul, 05505

  1 trial

  • NCT06717347A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    Contact: Study Coordinator

• Asan Medical Center (Site 3810)

  Seoul, 05505

  1 trial

  • NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

• Asan Medical Center (Site 4061)

  Seoul, 05505

  1 trial

  • NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

• Asan Medical Center (Site 4200)

  Seoul, 05505

  1 trial

  • NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

• Asan Medical Center (Site 4203)

  Seoul, 05505

  1 trial

  • NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

• Asan Medical Center (Site 5205)

  Seoul, 05505

  1 trial

  • NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Contact: Study Coordinator

• Asan Medical Center (Site 5800)

  Seoul, 05505

  1 trial

  • NCT07049926Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

    Contact: Study Coordinator

• Asan Medical Center (Site 5901)

  Seoul, 05505

  1 trial

  • NCT07232602KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

    Contact: Study Coordinator

• Asan Medical Center (Site 9901)

  Seoul, 05505

  1 trial

  • NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

    Contact: Study Coordinator

• Asan Medical Center (Site A)

  Seoul, 05505

  1 trial

  • NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

• Asan Medical Center (Site B)

  Seoul, 05505

  1 trial

  • NCT03776123Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

• Asan Medical Center,Substudy-02

  Seoul, 05505

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Asan Medical Center,Substudy-03

  Seoul, 05505

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Asan Medical Center - University of Ulsan College of Medicin

  Seoul, 05505

  1 trial

  • NCT03592472A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

    Contact: Sophia Paspal, Ph.D.

• Asan Medical Center: Urology Department

  Seoul

  1 trial

  • NCT02811861Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

• Asan Medical Centre - 3103

  Seoul, 05505

  1 trial

  • NCT05671510ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

• Asan Medical Centre,Substudy-01

  Seoul, 05505

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Cancer Center Clinical Trial, Asan Medical Center

  Seoul, 05505

  1 trial

  • NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

• Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center

  Seoul, 138-736

  1 trial

  • NCT05912972Development and Management of Registry in Patients With Gynecologic Cancer in Korea

    Contact: Jeong-Yeol Park, M.D., Ph.D.

• Department of Oncology, Asan Medical Center

  Seoul

  1 trial

  • NCT05243797Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

• Liver cancer center, Asan Medical Center

  Seoul, Song-pa 05505

  1 trial

  • NCT06819566Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC

    Contact: Ju Hyun Shim, MD, PhD

• University of Ulsan College of Medicine - Asan Medical Center

  Seoul, 05505

  1 trial

  • NCT04209855A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

• University of Ulsan College of Medicine - Asan Medical Center (AMC) - Cardiology Department

  Seoul, Seoul Teugbyeolsi 05505

  1 trial

  • NCT05686070A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke